Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Aileron Therapeutics, Inc. ALRN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
37/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Aileron Therapeutics, Inc. (ALRN) is a Biotechnology company in the Healthcare sector, currently trading at $2.11. It has a SharesGrow Score of 35/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Net income is $50M (loss), growing at -79.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $17M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 0.7 (tight liquidity). Debt-to-assets is 0%. Total assets: $24M.

Analyst outlook: 4 / 5 analysts rate ALRN as buy (80%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 90/100 (Pass), Income ?/100 (Fail).

ALRN SharesGrow Score Overview

46/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 90/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ALRN

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
ALRN: +0%/yr revenue is, -79.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet ALRN: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 0.7 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ALRN: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
90/100
Analyst outlook: 4 / 5 analysts rate ALRN as buy (80%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.61-7.42
Volume63.39K
Avg Volume (30D)101.12K
Market Cap$45.72M
Beta (1Y)2.34
Share Statistics
EPS (TTM)-1.96
Shares Outstanding$25.44M
IPO Date2017-06-29
Employees15
CEOJames Brian Windsor
Financial Highlights & Ratios
EBITDA$-50.63M
Net Income$-49.87M
Operating Income$-50.63M
Total Cash$3.22M
Net Debt$-3.22M
Total Assets$24.16M
Price / Earnings (P/E)-1.1
Analyst Forecast
Rating ConsensusBuy
Analysts Covering5
Buy 80% Hold 20% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS00887A2042

Price Chart

Track all markets on TradingView
ALRN
Aileron Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.61 52WK RANGE 7.42

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 CBIO
CBIO
Catalyst Biosciences, Inc.
$19.52
+8.50%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 BNTC
BNTC
Benitec Biopharma Inc.
$13.25
+10.42%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 MGTA
MGTA
Magenta Therapeutics, Inc.
$0.70
-7.74%
 SABS
SABS
SAB Biotherapeutics, Inc.
$3.86
-1.03%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message